Midatech Pharma PLC ADR
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.98 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Midatech Pharma PLC ADR had its IPO on 2015-12-07 under the ticker symbol MTP.
The company operates in the Healthcare sector and Biotechnology & Medical Research industry. Midatech Pharma PLC ADR has a staff strength of 20 employees.
Shares of Midatech Pharma PLC ADR opened at $0.14 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of $0.12 - $0.14, and closed at $0.13.
This is a +0.08% increase from the previous day's closing price.
A total volume of 1,148,193 shares were traded at the close of the day’s session.
In the last one week, shares of Midatech Pharma PLC ADR have slipped by -37.33%.
Midatech Pharma PLC ADR's Key Ratios
Midatech Pharma PLC ADR has a market cap of $1.98 million, indicating a price to book ratio of 0.6504 and a price to sales ratio of 5.0695.
In the last 12-months Midatech Pharma PLC ADR’s revenue was $645000 with a gross profit of $578000 and an EBITDA of $-7350000. The EBITDA ratio measures Midatech Pharma PLC ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Midatech Pharma PLC ADR’s operating margin was -1169.3% while its return on assets stood at -52.5% with a return of equity of -95.47%.
In Q1, Midatech Pharma PLC ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 16.7%.
Midatech Pharma PLC ADR’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.06 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Midatech Pharma PLC ADR’s profitability.
Midatech Pharma PLC ADR stock is trading at a EV to sales ratio of 0.0986 and a EV to EBITDA ratio of 0.0207. Its price to sales ratio in the trailing 12-months stood at 5.0695.
Midatech Pharma PLC ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $5.53 million
- Total Liabilities
- $1.90 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Midatech Pharma PLC ADR ended 2023 with $5.53 million in total assets and $0 in total liabilities. Its intangible assets were valued at $5.53 million while shareholder equity stood at $3.16 million.
Midatech Pharma PLC ADR ended 2023 with $0 in deferred long-term liabilities, $1.90 million in other current liabilities, 1108000.00 in common stock, $-135336000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2.84 million and cash and short-term investments were $2.84 million. The company’s total short-term debt was $161,000 while long-term debt stood at $0.
Midatech Pharma PLC ADR’s total current assets stands at $4.69 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $329000.00 compared to accounts payable of $1.45 million and inventory worth $0.
In 2023, Midatech Pharma PLC ADR's operating cash flow was $-8500.00 while its capital expenditure stood at $16500.
Comparatively, Midatech Pharma PLC ADR paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Midatech Pharma PLC ADR stock is currently trading at $0.13 per share. It touched a 52-week high of $20.8 and a 52-week low of $20.8. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.39 and 200-day moving average was $5.09 The short ratio stood at 2.12 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 2299.9% are held by institutions.
Frequently Asked Questions About Midatech Pharma PLC ADR
Similar Industry Stocks (Biotechnology & Medical Research)
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.